GLP‑1 news from 2013
2 dated, sourced GLP-1 developments from 2013: approvals, trial results, prices, lawsuits, compounding and culture.
- Business
Liraglutide 3.0 mg helped adults keep off lost weight in 56-week trial
In the SCALE Maintenance trial, 422 adults who had already lost at least 5% of their weight on a low-calorie diet were randomly assigned to daily liraglutide 3.0 mg or placebo for 56 weeks. The liraglutide group lost an additional 6.2% of their weight on average versus 0.2% with placebo, and 81.4% kept off the initial loss compared with 48.9%.
- Research and trials
Daily liraglutide lowered A1C more than weekly exenatide in head-to-head trial
In a 26-week trial published in The Lancet, once-daily liraglutide 1.8 mg lowered HbA1c by an average of 1.48 percentage points in adults with type 2 diabetes, compared with 1.28 points for once-weekly exenatide 2 mg. The 0.21-point difference failed the study's preset non-inferiority test, although exenatide caused far less nausea, 9 percent versus 21 percent. About 5 percent of liraglutide patients and 3 percent of exenatide patients stopped treatment because of side effects.